Struttura Complessa di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, via Venezia 16, Alessandria 15121, Italy.
Struttura Complessa di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, via Venezia 16, Alessandria 15121, Italy.
Hematol Oncol Clin North Am. 2020 Oct;34(5):887-901. doi: 10.1016/j.hoc.2020.06.006. Epub 2020 Aug 5.
Several biological and clinical features have been recognized in mantle cell lymphoma (MCL). In recent years, the minimal residual disease (MRD) has been extensively investigated and is now considered as one of the strongest clinical predictors in this lymphoma. This article reviews methods used for the assessment of MRD in MCL and discusses their strengths and weaknesses. In addition, it examines the MRD contribution to the biology knowledge of MCL and the development of effective strategies for its management, including the possibility of personalized treatment based on MRD response.
套细胞淋巴瘤(MCL)具有若干生物学和临床特征。近年来,微小残留病灶(MRD)已得到广泛研究,目前被认为是这种淋巴瘤中最强有力的临床预测指标之一。本文综述了用于评估 MCL 中 MRD 的方法,并讨论了它们的优缺点。此外,还探讨了 MRD 对 MCL 生物学知识的贡献,以及制定有效管理策略的可能性,包括基于 MRD 反应的个体化治疗。